Post Profile






See more about: Oxford BioMedica

Related Posts


Oxford BioMedica Announces US IND Approval For Novel Ocular Product In Usher Syndrome Type 1B

Health : Medical News Today

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) applic...

Oxford BioMedica wins big contract for Novartis cell therapy

Health : Reuters: Health

LONDON (Reuters) - Novartis has signed a major contract with Oxford BioMedica that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL...

Oxford BioMedica Announces Presentation Of New Clinical Data From ProSavin(R) Phase I/II Study In Parkinson's Disease

Health : Medical News Today

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin® for the treatment of Parkinson's disease (PD) were presen...

Oxford BioMedica Announces Ocular Programme Update

Health : Medical News Today

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that the first dose level of RetinoStat(R) is safe and well-tolerated at one month following treatment. RetinoSta...

Profit finally in sight for gene therapy specialist Oxford Bio

Health : Reuters: Health

LONDON (Reuters) - After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneering cancer treatment.

Comments


Copyright © 2016 Regator, LLC